MY170303A - Oral formulations of deferasirox - Google Patents

Oral formulations of deferasirox

Info

Publication number
MY170303A
MY170303A MYPI2015702695A MYPI2015702695A MY170303A MY 170303 A MY170303 A MY 170303A MY PI2015702695 A MYPI2015702695 A MY PI2015702695A MY PI2015702695 A MYPI2015702695 A MY PI2015702695A MY 170303 A MY170303 A MY 170303A
Authority
MY
Malaysia
Prior art keywords
deferasirox
oral formulations
neutral
disclosed
formulations
Prior art date
Application number
MYPI2015702695A
Other languages
English (en)
Inventor
Indrajit Ghosh
Jia-Ai Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50288212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY170303(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MY170303A publication Critical patent/MY170303A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2015702695A 2013-03-08 2014-03-06 Oral formulations of deferasirox MY170303A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361774893P 2013-03-08 2013-03-08
US201361824435P 2013-05-17 2013-05-17

Publications (1)

Publication Number Publication Date
MY170303A true MY170303A (en) 2019-07-17

Family

ID=50288212

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015702695A MY170303A (en) 2013-03-08 2014-03-06 Oral formulations of deferasirox

Country Status (42)

Country Link
US (4) US9283209B2 (https=)
EP (2) EP3124018B2 (https=)
JP (3) JP6434429B2 (https=)
KR (2) KR20170045391A (https=)
CN (1) CN105025886B (https=)
AP (1) AP2015008668A0 (https=)
AU (2) AU2014224198B2 (https=)
BR (1) BR112015021254A2 (https=)
CA (1) CA2890465A1 (https=)
CL (1) CL2015002495A1 (https=)
CR (1) CR20150467A (https=)
CU (1) CU24348B1 (https=)
CY (2) CY1120021T1 (https=)
DK (2) DK3124018T3 (https=)
DO (1) DOP2015000220A (https=)
EA (1) EA031719B1 (https=)
EC (1) ECSP15042897A (https=)
ES (2) ES2663135T5 (https=)
GE (1) GEP20186810B (https=)
HR (2) HRP20190173T1 (https=)
HU (2) HUE036921T2 (https=)
IL (1) IL240797B (https=)
JO (1) JO3570B1 (https=)
LT (2) LT3124018T (https=)
ME (1) ME03297B (https=)
MX (1) MX361055B (https=)
MY (1) MY170303A (https=)
NI (1) NI201500126A (https=)
NZ (1) NZ711179A (https=)
PE (1) PE20151600A1 (https=)
PH (1) PH12015501981B1 (https=)
PL (2) PL2964202T3 (https=)
PT (2) PT3124018T (https=)
RS (2) RS56890B1 (https=)
SA (1) SA515360425B1 (https=)
SG (2) SG10201807204YA (https=)
SI (2) SI3124018T1 (https=)
TN (1) TN2015000393A1 (https=)
TW (2) TWI686215B (https=)
UY (1) UY35367A (https=)
WO (1) WO2014136079A1 (https=)
ZA (1) ZA201506060B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20190173T1 (hr) 2013-03-08 2019-03-22 Novartis Ag Oralne formulacije deferasiroksa
US9866684B2 (en) * 2015-02-16 2018-01-09 Microsoft Technology Licensing, Llc Process for real-time data exchange between users on a phone call
WO2016167729A1 (en) * 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
MA43271A (fr) 2015-06-17 2018-09-26 Dispersol Technologies Llc Formulations améliorées de déférasirox et leurs procédés de fabrication
WO2017158559A1 (en) 2016-03-17 2017-09-21 Lupin Limited Compositions of deferasirox
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2018007956A1 (en) * 2016-07-05 2018-01-11 Jubilant Generics Limited Immediate release pharmaceutical composition of iron chelating agents
EP3518904A1 (en) 2016-09-30 2019-08-07 Synthon B.V. Pharmaceutical composition comprising deferasirox
CZ2017255A3 (cs) * 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
TR201707764A2 (tr) * 2017-05-29 2018-12-21 Biofarma Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasiroksun bölünebilir tablet formları.
WO2019108156A1 (en) * 2017-11-28 2019-06-06 Biofarma Ilac Sanayi Ve Ticaret A.S. A scored tablet formulation comprising deferasirox in a film tablet form
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제
EP3854385A1 (en) * 2020-01-27 2021-07-28 ROS Therapeutics ApS Methotrexate dosage form
EP4052698A1 (en) * 2021-03-05 2022-09-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Film coated tablet comprising deferasirox
CN117440800A (zh) * 2021-06-07 2024-01-23 R·P·舍勒科技有限责任公司 用于对水分敏感的药物组合物的保护性包衣
CN115154428B (zh) * 2022-09-06 2023-01-10 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法
WO2025242589A1 (en) 2024-05-21 2025-11-27 Chiesi Farmaceutici S.P.A. Pharmaceutical dosage forms for deferiprone and deferasirox combined therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY129541A (en) * 1996-06-25 2007-04-30 Novartis Ag Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
KR20070022243A (ko) * 2004-04-08 2007-02-26 노파르티스 아게 데페라시록스 분산성 정제
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
BRPI0617715A2 (pt) 2005-10-19 2011-08-02 Novartis Ag comprimidos dispersìveis compreendendo deferasirox
WO2009067557A1 (en) 2007-11-19 2009-05-28 Teva Pharmaceutical Industries Ltd. Deferasirox pharmaceutical compositions
WO2009106824A2 (en) 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
US20110097413A1 (en) 2008-04-21 2011-04-28 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
WO2010035282A1 (en) 2008-09-24 2010-04-01 Matrix Laboratories Limited Pharmaceutical compositions comprising deferasirox
WO2010143006A1 (en) * 2009-06-10 2010-12-16 Carlo Ghisalberti Orally bioavailable iron chelators in the treatment of an inflammatory bowel disease
ES2543427T3 (es) * 2010-07-08 2015-08-19 Ratiopharm Gmbh Forma farmacéutica oral de deferasirox
MX2013003522A (es) 2010-10-01 2013-05-22 Cipla Ltd Composicion farmaceutica.
HRP20190173T1 (hr) 2013-03-08 2019-03-22 Novartis Ag Oralne formulacije deferasiroksa
WO2017158559A1 (en) 2016-03-17 2017-09-21 Lupin Limited Compositions of deferasirox

Also Published As

Publication number Publication date
KR20170045391A (ko) 2017-04-26
TWI625136B (zh) 2018-06-01
TW201442742A (zh) 2014-11-16
SI2964202T1 (sl) 2019-02-28
CU20150110A7 (es) 2016-04-25
GEP20186810B (en) 2018-01-25
JP6739470B2 (ja) 2020-08-12
ZA201506060B (en) 2016-12-21
EP2964202B1 (en) 2018-10-31
EA201591665A1 (ru) 2015-12-30
CN105025886A (zh) 2015-11-04
JP2016510068A (ja) 2016-04-04
JP2018162255A (ja) 2018-10-18
MX361055B (es) 2018-11-26
SG11201506491RA (en) 2015-09-29
CL2015002495A1 (es) 2016-03-04
EA031719B1 (ru) 2019-02-28
PH12015501981A1 (en) 2016-01-11
RS56890B1 (sr) 2018-04-30
KR101925671B1 (ko) 2019-02-27
US20170290811A1 (en) 2017-10-12
ES2663135T5 (en) 2024-12-16
EP2964202A1 (en) 2016-01-13
NZ711179A (en) 2018-07-27
US20150017241A1 (en) 2015-01-15
DOP2015000220A (es) 2015-11-30
CU24348B1 (es) 2018-05-08
MX2015011962A (es) 2016-07-07
CY1121315T1 (el) 2020-05-29
AP2015008668A0 (en) 2015-08-31
ES2663135T3 (es) 2018-04-11
ES2708955T3 (es) 2019-04-12
EP3124018B2 (en) 2024-04-24
HRP20180387T1 (hr) 2018-04-20
PT2964202T (pt) 2019-02-06
JP2020180123A (ja) 2020-11-05
SG10201807204YA (en) 2018-09-27
LT3124018T (lt) 2018-03-12
BR112015021254A2 (pt) 2017-07-18
HUE041224T2 (hu) 2019-05-28
NI201500126A (es) 2015-11-18
US9283209B2 (en) 2016-03-15
UY35367A (es) 2014-10-31
WO2014136079A1 (en) 2014-09-12
CY1120021T1 (el) 2018-12-12
AU2014224198B2 (en) 2017-06-15
JO3570B1 (ar) 2020-07-05
PL2964202T3 (pl) 2019-04-30
KR20150126900A (ko) 2015-11-13
RS58317B1 (sr) 2019-03-29
TW201838623A (zh) 2018-11-01
PL3124018T3 (pl) 2018-05-30
CA2890465A1 (en) 2014-09-12
PT3124018T (pt) 2018-03-22
ECSP15042897A (es) 2019-03-29
EP2964202B2 (en) 2023-05-31
AU2017203897B2 (en) 2019-02-14
AU2017203897A1 (en) 2017-06-29
IL240797A0 (en) 2015-10-29
SA515360425B1 (ar) 2018-01-21
PH12015501981B1 (en) 2016-01-11
CN105025886B (zh) 2019-01-15
TWI686215B (zh) 2020-03-01
DK3124018T3 (en) 2018-03-26
HK1212242A1 (en) 2016-06-10
IL240797B (en) 2022-01-01
SI3124018T1 (en) 2018-04-30
AU2014224198A1 (en) 2015-09-10
EP3124018A1 (en) 2017-02-01
ME03297B (me) 2019-07-20
ES2708955T5 (es) 2023-11-10
JP6434429B2 (ja) 2018-12-05
TN2015000393A1 (en) 2017-01-03
US20180221285A1 (en) 2018-08-09
HUE036921T2 (hu) 2018-08-28
HRP20190173T1 (hr) 2019-03-22
PE20151600A1 (es) 2015-11-26
LT2964202T (lt) 2019-02-11
US20160220493A1 (en) 2016-08-04
CR20150467A (es) 2015-10-27
DK2964202T3 (en) 2019-02-25
EP3124018B1 (en) 2017-12-20

Similar Documents

Publication Publication Date Title
MY170303A (en) Oral formulations of deferasirox
IL261479B1 (en) The cannabinoid composition is encapsulated in a blister for oral administration
ZA201805634B (en) Conjugate of therapeutic enzymes
IL258185B (en) Oleanolic acid derivatives are modified at carbon 4 for il–17 inhibition and other uses
EP3302556A4 (en) Human cell lines mutant for zic2
PL3582626T3 (pl) Formulacje dyspergowalne w wodzie
EP3258925A4 (en) METHOD AND COMPOSITIONS FOR REDUCING MAGENTAL EMISSIONS
DK3244878T3 (da) Faste orale sammensætningsformer
EP3268125A4 (en) Determination of cells using amplification
EP3280398A4 (en) Self-emulsifying formulations of dim-related indoles
EP3620156A4 (en) COMPOSITION WITH IMPROVED WATER SOLUBILITY AND BIOAVAILABILITY
EP3376995A4 (en) BALLOON SHUTTER FOR COLOSTOMY
ZAA201800662S (en) Tab
EP3107543A4 (en) Vacuolin-1 as an inhibitor of autophagyand endosomal trafficking and the use thereof for inhibiting tumor progression
EP3256135A4 (en) Methods of preventing secondary infections
GB2535688B (en) Pipe isolation & intervention
EP3253394A4 (en) Scaffold-seeded oral mucosa stem cells
ITUB20153699A1 (it) Integratore orale
AU2016904714A0 (en) An improved male undergarment
AU2017901767A0 (en) An improved male undergarment
AU2017904857A0 (en) Improved underwear
UA103911U (ru) Средство с вазодилатирующей активностью
AU2017900780A0 (en) Improved floating connection for walls
AU2016901560A0 (en) Construction of Pipes
AU2014903744A0 (en) Nitrification inhibitors and formulations